

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/033,491-Conf. #9920
				Filing Date	December 27, 2001
				First Named Inventor	Shuyuan Zhang
				Art Unit	1633
				Examiner Name	R. M. Kelly
Sheet	1	of	2	Attorney Docket Number	29853/37706

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	US-2004/0229335	11-18-2004	Zhang et al.	
	A2	US-60/082,62	12-28-1999	McKay et al.	
	A3	US-5,219,752	06-15-1993	Takazawa Yoshiharu et al.	
	A4	US-5,604,096	02-18-1997	Schaeffer et al.	
	A5	US-6,194,191	02-27-2001	Zhang et al.	
	A6	US-6,410,010	06-25-2002	Zhang et al.	
	A7	US-6,726,907	04-27-2004	Zhang et al.	
	A8	US-6,740,320	05-25-2004	Zhang et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B1	WO-1990/08444	07-26-1990	Telefunken Fernseh Und Rundfunk GMBH		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	DEONARAIN, Ligand-targeted receptor-mediated vectors for gene delivery, Exp. Opin. Ther. Pat., 8:53-69, 1998.	
	C2	ECK et al., Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th edition, McGraw-Hill, New York, NY, 77-101, 1996.	
	C3	GORECKI, Prospects and problems of gene therapy: an update, Exp. Opin. Emerging Drugs, 6:187-198, 2001.	
	C4	GREEN et al., Adenoviral vectors: systemic delivery and tumor targeting, Cancer Gene Ther., 9:1036-1042, 2002.	
	C5	KOTANI, Serum-free production of adenoviral vectors for gene therapy, Williamsburg BioProcessing Conference, November 18-21, 1996.	
	C6	Office Action, U.S. Application Serial No. 08/975519, United States Patent and Trademark Office, mailed 24 June 1999.	
	C7	Office Action, U.S. Application Serial No. 08/975519, United States Patent and Trademark Office, mailed 25 September 1998.	
	C8	Office Action, U.S. Application Serial No. 09/203,078, United States Patent and Trademark Office, mailed 20 March 2001.	
	C9	Office Action, U.S. Application Serial No. 09/203,078, United States Patent and Trademark Office, mailed 13 September 2001.	
	C10	Office Action, U.S. Application Serial No. 09/203,078, United States Patent and Trademark Office, mailed 3 October 2003.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/033,491-Conf. #9920
				Filing Date	December 27, 2001
				First Named Inventor	Shuyuan Zhang
				Art Unit	1633
				Examiner Name	R. M. Kelly
Sheet	2	of	2	Attorney Docket Number	29853/37706

	C11	Office Action, U.S. Application Serial No. 09/203,078, United States Patent and Trademark Office, mailed 17 November 2004.	
	C12	Office Action, U.S. Application Serial No. 09/556,570, United States Patent and Trademark Office, mailed 24 February 2003.	
	C13	Office Action, U.S. Application Serial No. 09/556,570, United States Patent and Trademark Office, mailed 23 April 2002.	
	C14	Office Action, U.S. Application Serial No. 09/556,570, United States Patent and Trademark Office, mailed 29 June 2001.	
	C15	Office Action, U.S. Application Serial No. 10/033,571, United States Patent and Trademark Office, mailed 16 March 2007.	
	C16	Office Action, U.S. Application Serial No. 10/033,571, United States Patent and Trademark Office, mailed 22 June 2004.	
	C17	Office Action, U.S. Application Serial No. 10/033,571, United States Patent and Trademark Office, mailed 21 October 2004.	
	C18	Office Action, U.S. Application Serial No. 10/033,571, United States Patent and Trademark Office, mailed 11 July 2005.	
	C19	Office Action, U.S. Application Serial No. 10/033,571, United States Patent and Trademark Office, mailed 2 May 2006.	
	C20	Office Action, U.S. Application Serial No. 10/909,066, United States Patent and Trademark Office, mailed 6 September 2007.	
	C21	Office Action, U.S. Application Serial No. 10/909,066, United States Patent and Trademark Office, mailed 10 July 2006.	
	C22	Office Action, U.S. Application Serial No. 10/909,066, United States Patent and Trademark Office, mailed 18 December 2006.	
	C23	PELTEKIAN et al., Adenovirus-mediated gene transfer to the brain: methodological assessment, J. Neurosci. Meth., 71:77-84, 1997.	
	C24	ROWE et al., Complementation of adenovirus type 5 host range mutants by adenovirus type 12 in coinfecting HeLa and BHK-21 cells, J. Virol., 38:191-197, 1994.	
	C25	Communication pursuant to Article 96(2) EPC, EP 06012869.1, European Patent Office, 15 June 2007.	
	C26	Communication pursuant to Article 96(2) EPC, EP 06025694.8, European Patent Office, 14 June 2007.	
	C27	GREEN et al., Biochemical studies on adenovirus multiplication: kinetics of nucleic acid and protein synthesis in suspension cultures, Virology, 13:169-176, 1961.	
	C28	GRIFFITHS, Scaling up of animal cell cultures, Animal Cell Cultures: A Practical Approach, 2 nd edition, edited by Freshney, 3:47-93, 1992.	
	C29	KAWAKUBO et al., Tissue plasminogen activator (t-PA) production by a high density culture of weakly adherent human embryonic kidney cells using a polyurethane-foam packed-bed culture system, Appl. Microbiol. Biotechnol., 41:413-418, 1994.	
	C30	MANN et al., 3 rd General Meeting of ESACT, Oxford, Develop. Biol. Standard, 46:289-294, 1980.	
	C31	Notice of Opposition to a European Patent, EP 0968284, European Patent Office, 12 September 2007.	
	C32	WANG et al., Studies on high-density cultivation of Vero cells with biosilon solid microcarrier, Chinese J. Biotechnol., 12:119-129, 1996.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--